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In the last decades, radiotherapy (RT) has become one of the cornerstones in the
treatment of head and neck (HN) malignancies and has paralleled an increase in
long-term patient survival. This lead to a concomitant increase in the incidence of
radiation-induced sarcomas (RIS) of the irradiated field, with an annual rate up to 0.17%.
The new techniques of irradiation do not seem to influence the risk of RIS of the HN
(RISHN), whichmainly develop within themiddle-dose field. Themedian latency of RISHN
after RT is 10–12 years and osteosarcoma is the most represented histotype, even
though there is a high variability in time of occurrence and histological features observed.
There is no clear evidence of predisposing factors for RISHN, and genetic findings so far
have not revealed any commonmutation. Early clinical diagnosis of RISHN is challenging,
since it usually occurs within fibrotic and hardened tissues, while radiological findings are
not pathognomonic and able to differentiate them from other neoplastic entities. Given
the highly aggressive behavior of RISHN and its poor sensitivity to chemotherapy, radical
surgery is the most important prognostic factor and the only curative option at present.
Nevertheless, the anatomy of the HN district and the infiltrative nature of RIS do not
always allow radical intervention. Therefore, a wise integration with systemic therapy
and, when feasible, re-irradiation should be performed. Future findings in the genomic
features of RISHN will be crucial to identify a possible sensitivity to specific drugs in order
to optimize a multimodal treatment that will be ideally complementary to surgery and
re-irradiation.
Keywords: sarcoma, head and neck, radiotherapy, radiation-induced, surgical treatment
INTRODUCTION
The long-term carcinogenic potential of ionizing radiations is well known and has been described
since 1902 (1). In the last decades an increased number of radiation-induced (RI) neoplasia have
been observed, due to—among other reasons—a substantial improvement of patients survival (2).
The commonest histological subtypes of RI tumors are squamous cell carcinoma (SCC) followed by
Giannini et al. Head and Neck Radiation-Induced Sarcomas
sarcoma, even though many types of cancers have been possibly
described after radiotherapy (RT) (3).
RI sarcomas of the head and neck (RISHN) are very
rare entities, and characterized by poor long-term outcomes.
Their incidence is quite low and variable: among the largest
retrospective studies available in the literature, the reported
annual incidence is 0.06–0.17% (4), compared to a 1.6% incidence
when all body RIS are considered (5). As a matter of fact, even a
retrospective study performed at the National Cancer Institute of
Milan, Italy, the leading center for treatment of sarcoma in our
country, found only 5 cases of possible RISHN among 206 SHN
treated between 1990 and 2010 (6).
The median time of latency after RT is reported to be 10–
12 years, while the arbitrary cut-off used to distinguish RIS
from sporadic sarcomas is 3–4 years after RT. However, it seems
that the time of occurrence of cutaneous angiosarcoma, for
example, may be shorter than for other histotypes (4, 6–8).
Moreover, a recent multicenter study showed how the association
of chemotherapy may significantly shorten the latency of the
RI-related second tumor occurrence (8).
There is no evidence of a specific site in the HN in which
RISs preferentially occur, even though different Chinese studies
indicate the paranasal sinuses as the most commonly affected
region (4, 9). However, this seems to be a bias due to the high
prevalence of nasopharyngeal cancer in the Eastern population,
with the nasopharynx and paranasal sinuses being the most
irradiated subsites in such an epidemiological scenario.
In the current literature there is a substantial paucity of
updated and comprehensive reviews on RISHNs. Moreover,
many reports tend to analyze only clinical records from their own
center, nearly always considering patients treated in a long time
span, even several decades before, by obsolete treatments. In this
way, there is a concrete risk to apply outdated data and concepts
to the modern scenario, characterized by completely different RT
techniques and therapeutic algorithms.
The aim of the present review is therefore to offer an up-to-
date summary on this topic, with special emphasis to the ultimate
molecular findings, RT technologies, and treatment possibilities
of such a devastating disease.
RADIATION AND CARCINOGENESIS
Even though the effects of radiations in humans have been
described since the beginning of the twentieth century, only the
incidence and mortality for solid cancers and leukemia among
nuclear bomb survivors in Japan provided us with the basis
for understanding the functional dose-response relationships
(10). Firstly, there is no “safety threshold” below which second
malignancies may not occur, although a consistent number of
dosimetric studies found that RI tumors occur close to the
primary field of RT (within 5 cm) in a variable rate of 43–90% of
patients (10). This can be explained by the main outcome of RT
within the high-dose region, represented by the cell-killing effect,
while the cellular repopulation in the surrounding areas receiving
a lower dose would favor the clonal maintenance of mutated lines
(10). It has been suggested that the highest risk of RImalignancies
may be observed at sublethal cellular doses (6); nevertheless, a
reduction in risk at high doses has not been shown, except for
thyroid cancer (11).
Another issue on which the literature has recently focused its
attention is the use of new RT techniques, with associated long-
term risks. Intensity modulated radiation therapy (IMRT) and
volumetric modulated arc therapy (VMAT) are nowadays the
most common methods of RT used to treat HN tumors. These
techniques consist in an evolution of the three-dimensional
conformal RT (3D-CRT), in which it is possible to refine the
high-dose conformity around cancers with complex shapes, in
order to reduce the dose received by surrounding organs (12).
This allows irradiating the target tissue with higher doses, while
simultaneously reducing the dose delivered to areas close to
the lesion. From a functional point of view, these techniques
ensure less acute toxicity than traditional RT while, on the other
hand, the low-dose irradiation fields become wider (12, 13). The
worries about such techniques are based on the aforementioned
principle of a relatively high impact of low-dose irradiation, in
contrast with the high rate of cell death observed in high-dose
areas. In fact, some authors have argued that IMRT/VMAT are
likely to almost double the incidence of second malignancies
compared with conventional RT techniques from about 1 to
1.75% for patients surviving 10 years (14). However recent
studies including large series of patients did not find significant
differences between IMRT, VMAT, and 3D-CRT in terms of
second primary cancer risk (15, 16). Indeed, it cannot be ruled
out that the potentially damaging consequences of the larger
low-dose component surrounding the target in IMRT/VMAT are
balanced by the higher cancerogenic effects observed in a smaller
area receiving an intermediate-dose in 3D-CRT (12).
Also intensity modulated proton therapy (IMPT) is a
promising approach to reduce commonly seen post-RT acute
and chronic adverse effects (13). However, costs of IMPT
greatly exceed those of IMRT and world-wide capacity of
implementation of such a technique is, so far, rather limited. As a
consequence, knowledge of IMPT effects on RISHN are still scant
and far to be quantitatively meaningful.
Even the role of carbon ion radiotherapy is now under
investigation, especially for management of recurrent HN cancer
and RIS. This technique produces a higher linear energy transfer
with greater relative biological effectiveness compared to photon
and proton beams (14). However, even in this field, before seeing
a substantial change in RIS epidemiology we will probably need
some decades from now.
GENOMIC CORRELATIONS
The mechanisms involved in the cancerogenesis of RIS are
represented by damage to double-stranded DNA, resulting
in genomic instability (17). Many studies have looked for
mutations implicated in the etiology of RIS: for example, it
has been demonstrated the role of cMyc amplification in RI
angiosarcomas, which is not found in other types of RIS (18).
Other authors have investigated the role of the tumor
suppressor retinoblastoma 1 (RB1) levels in osteoblasts in
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the occurrence of RI osteosarcoma (RIOS) (19). In fact, RB1
activation induces the expression of a panel of proteins called
senescence-associated secretory phenotypes (SASP), that is
formed by cytokines (with interleukine-6 the most important)
and complement proteins (19). During RT, the RB1-SASP
pathway initiates a process of cellular senescence, resulting in
immunologic recognition of damaged cells by natural killer T
cells. A lack of this oncosuppressive system, due to the mutagenic
potential of RT, may favor the occurrence of RIS (19).
Moreover, Hadj-Hamou et al. performed a comparative
analysis in transcriptome modification between RIS and sporadic
sarcomas (20). It was found that RIS are characterized by
mitochondrial dysfunction that may be at the origin of a chronic
endogenous oxidative stress: it is likely that such a phenomenon
causes the alterations in pathways that lead to RIS (20).
For what concerns the HN region, recent studies examined
the change in expression of p53 and one of its regulator proteins
Murine Double Minute 2 (Mdm2), comparing their levels in de
novo and in RIS (21). It was seen that p53 was overexpressed
in RIS, while Mdm2 amplification was more represented in
de novo tumors (21). Moreover, Mdm2-p53 interaction has
gained interest in the last years, since a better response to
chemotherapy was found in patients Mdm2+/p53– in well-
differentiated/dedifferentiated liposarcomas (22). However, only
a minimal percentage of RISHN presents with this combination,
making the widespread possibility of usingMdm2 inhibitors very
unlikely (21, 22).
CLINICAL AND RADIOLOGICAL FEATURES
Zhu et al. summarized the features of 323 cases of RISHN
in the literature, finding RIOS as the most common
(34.1%) histotype, followed by fibrosarcoma (RIFS, 19.2%),
undifferentiated pleomorphic sarcoma (RIUPS, 15.8%),
previously named malignant fibrous histiocytoma, not
otherwise specified sarcoma (10.7%), leiomyosarcoma (5.6%),
and rhabdomyosarcoma (3.8%) (23). Other less common
histological findings were malignant peripheral nerve sheath
tumor, chondrosarcoma, angiosarcoma, carcinosarcoma,
dermatofibrosarcoma, Kaposi’s sarcoma, liposarcoma, low-grade
myofibroblastic sarcoma, myofibroblastoma, and synovial
sarcoma (23). This high variability was not reported in
previous studies, in which RIUPS was the predominant
histological subtype. This is probably due to recent advances
in pathologic classification and diagnosis of sarcomas (24).
For this reasons, the diagnosis of RIFS, even though still
present in many retrospective studies, has been limited
during the latest decades and divided into: fibromyxoid
sarcoma, sclerosing epithelioid sarcoma, dermatofibrosarcoma
protuberans, and fibrosarcomatous dermatofibrosarcoma
protuberans (25).
The average latency between RT and RIS diagnosis is quite
constant in most studies, even if the reported range can be
extremely large (from <1 to 50 years) (23). Nonetheless, even
though a minimum latency period of a few years has been
routinely used to distinguish RISHN from de novo sarcomas,
the majority of epidemiologic studies did not consider this time
frame and also included early post-RT sarcomas.
From a clinical point of view, the early identification
of RISHN may be difficult to make due to the induration
and fibrosis of the irradiated field (26). The most common
symptoms, essentially related to the site of occurrence of
the tumor itself, are: asymmetry of the HN region, pain,
trismus, epistaxis, diplopia, jaw numbness, and dysphagia, while
sometimes RIS may be misdiagnosed as osteoradionecrosis (23,
26). Furthermore, the overall features of RISHN and de novo
sarcomas make it impossible to define a clear distinction between
these two entities: in fact, median age, gender ratio, median
tumor size, and tumor grade are similar between RIS and
osteoradionecrosis (27).
Radiological findings may be challenging due to the
heterogeneous characteristics of RIS on CT and/or MR.
Generally, RISHN may not be easily distinguished from primary
cancer recurrence and/or second primary lesions but, in presence
of a large size, rapidly growing, extensively invading, bony
destructive lesion with highly heterogeneous appearance, and
significant contrast enhancement, RISHN should be always
suspected as the most probable entity (24).
On the other hand, RIOS is one of the RISHN that presents
with sufficient differences to be distinguished from primary OS.
In fact, the latter usually presents, in MR, with an intermediate
T1-signal and marked T2-hyperintensity, while in RIOS T1-
T2 findings are unpredictable and variable with a frequent
presence of bony erosion (26). Moreover, the presence of an
osteoid matrix does not correlate with the FDG uptake which
in RIOS is frequently reduced, making such an interpretation
much more complex (26). Finally, signals of RIOS are mainly
solid and it may be confounded with more differentiated RI
malignancies, such as meningioma (26). All these features are
not coherent with de novo OS, and the variability of the
related findings makes the spectrum of differential diagnoses
wider.
TREATMENT AND PROGNOSIS
RIS are historically considered highly aggressive tumors,
characterized by poor prognosis. Yeang et al. found an age
more than 50, smoking history, tumor size, and grading to be
significant negative prognosticators (27). However, most of the
reports analyzed RISHN as if they were a single entity, even
though, indeed, they include a wide range of possible histotypes,
as mentioned above.
A recent study compared RIFS with its de novo counterpart:
survival in patients treated for the former disease was
significantly lower than that of the sporadic form (38.6
vs. 52.6% 5-year disease-specific survival, p = 0.0219). The
authors suggested that this may be mainly determined by the
impossibility to retreat patients with RT, one of the most
important pillars of the therapeutic armamentarium (28). In
fact, patients presenting these lesions less likely undergo further
radiation treatment, while chemotherapy appears to be of limited
benefit (28, 29).
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The highly aggressive nature of RISHN, the frequent lack
of feasibility of re-irradiation, and its limited chemosensitivity
make surgery the most important treatment able to improve
patient survival. Indeed, as for non-RIS, a significant increase
in disease-specific and overall survivals has been shown in
patients with macroscopically complete resection compared
to cases in which incomplete surgery or re-irradiation alone
had been performed (30). However, obtaining a resection
with microscopically negative margins is not always possible,
due to the nature of the lesion, RT-related sequelae, and
the peculiarity of the HN anatomy. Moreover, during their
growth RISHN do not respect fascial planes, and they often
require wider and atypical resections (30). As a consequence,
the surgical option is sometimes refused by the patient for
the highly disfiguring and/or dysfunctional outcomes, while
the aggressiveness necessary for an adequate resection may
threaten vital or crucial structures, leading surgeons to seek
for a compromise between quality of surgery and unbearable
sequelae (30). For this reason, neoadjuvant therapy with re-
irradiation (even though possible in <20% of cases) with or
without chemotherapy (4, 27), when feasible, may be of help (31).
This, indeed, underlies the absolute need for a comprehensive
multidisciplinary approach in such a clinical scenario, in order
to look for adjunctive tools in the management of a quite dismal
disease.
CONCLUSIONS
RISHN are rare and heterogeneous oncologic entities, with
multiple atypical aspects in terms of occurrence, subtypes,
clinical-radiological features, and therapeutic opportunities,
which make the disease highly challenging to manage, stressing
the need for evaluation by a multidisciplinary team in reference
centers for treatment of sarcomas. IMRT/VMAT does not seem
to increase the rate of post-RT sarcomas, even if further long-
term studies are needed to validate the results found in the
literature. Complete surgery remains the cornerstone of therapy.
Genetic studies have not found any crucial mutations in RISHN,
even though further investigations might be very helpful in
finding possible new and effective drugs.
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